Chengdu Kanghua Biological Products Co., Ltd.

隶属于 aokang group co. ltd.

The company was founded in 2004, and in September 2018, the company further expanded its scale and signed a contract with the Wenjiang District Government of Chengdu to select the site in Area A of the International Medical City as a research and development base for the novel vaccine. The company is equipped with an animal testing center and a high-tech GMP production workshop for bacterial and viral vaccines. Existing products include “ACYW135 meningococcal polysaccharide vaccine” (trade name: Microsin) and “freeze-dried human rabies vaccine (human diploid cells)” (trade name: HDCV). The company's main business focuses on the biomedical field. It is a vaccine manufacturer integrating comprehensive research, development and operation, and is also the first domestic vaccine company to produce and sell human diploid cell rabies vaccine. The company's main products are freeze-dried human rabies vaccine (human diploid cells) and ACYW135 meningococcal polysaccharide vaccine. Corporate honors: Since its establishment, it has successively been awarded honorary titles such as “Postdoctoral Innovation Practice Base”, “Sichuan Province Constructive Innovation Enterprise Cultivating Enterprise”, and “Sichuan Excellent Integrity Demonstration Unit” by the Department of Personnel and the Science and Technology Department, etc., and has passed GMP certification by the China Food and Drug Administration. In recent years, Kanghua Biotech has undertaken several scientific and technological projects and applied for patent protection for more than 100 technologies; the company's freeze-dried human rabies vaccine (human diploid cells) has successively been awarded honorary titles such as “National Key New Product” and “Strategic Emerging Product of Sichuan Province”.